Skip to main content
SpringerLink
Log in

Is Heart Rate a Norepiphenomenon in Heart Failure?

  • Heart Failure (MR Mehra and E Joyce, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

There has been an increased focus on heart rate as a target in the management of cardiovascular disease and more specifically in heart failure with preserved ejection fraction in recent years with several studies showing the benefit of a lower resting heart rate on outcomes. This review paper examines the pathophysiology behind the benefits of lowering heart rate in heart failure and also the evidence for and against the pharmacological agents available to achieve this.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol. 1997;30(4):1104–6.

    Article  CAS  PubMed  Google Scholar 

  2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Al-Mohammad A, Mant J, Laramee P, Swain S. Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. BMJ (Clin Res Ed). 2010;341:c4130.

    Article  Google Scholar 

  4. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215.

    Article  PubMed  Google Scholar 

  5. Ferrari R, Ford I, Fox K, Steg PG, Tendera M. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction—baseline characteristics of the study population. Cardiology. 2008;110(4):271–82.

    CAS  PubMed  Google Scholar 

  6. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.

    Article  CAS  PubMed  Google Scholar 

  7. US Food and Drug Administration. FDA approves Corlanor to treat heart failure 2015 [cited 2016 8 March]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm442978.htm.

  8. Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol: Off J Soc Cardiovasc Pathol. 2012;21(5):365–71. This article provides an excellent review of the pathophysiology of heart failure.

    Article  CAS  Google Scholar 

  9. Lee CS, Tkacs NC. Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN advanced critical care. 2008;19(4):364–85; quiz 86–7.

  10. Chidsey CA, Harrison DC, Braunwald E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med. 1962;267:650–4.

    Article  CAS  PubMed  Google Scholar 

  11. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307(4):205–11.

    Article  CAS  PubMed  Google Scholar 

  12. Lefkowitz RJ, Mukherjee C, Coverstone M, Caron MG. Stereospecific (3H)(minus)-alprenolol binding sites, beta-adrenergic receptors and adenylate cyclase. Biochem Biophys Res Commun. 1974;60(2):703–9.

    Article  CAS  PubMed  Google Scholar 

  13. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, et al. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol. 1984;54(7):783–6.

    Article  CAS  PubMed  Google Scholar 

  14. Rose CP, Burgess JH, Cousineau D. Tracer norepinephrine kinetics in coronary circulation of patients with heart failure secondary to chronic pressure and volume overload. J Clin Invest. 1985;76(5):1740–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615–21.

    Article  CAS  PubMed  Google Scholar 

  16. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic nervous system in heart failure. Am J Cardiol. 1997;80(11a):7l–14l.

    Article  CAS  PubMed  Google Scholar 

  17. Curry CW, Nelson GS, Wyman BT, Declerck J, Talbot M, Berger RD, et al. Mechanical dyssynchrony in dilated cardiomyopathy with intraventricular conduction delay as depicted by 3D tagged magnetic resonance imaging. Circulation. 2000;101(1), E2.

    Article  CAS  PubMed  Google Scholar 

  18. Gillman MW, Kannel WB, Belanger A, D’Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125(4):1148–54.

    Article  CAS  PubMed  Google Scholar 

  19. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet (London, England). 2010;376(9744):875–85.

    Article  CAS  Google Scholar 

  20. Kannel WB, Kannel C, Paffenbarger Jr RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987;113(6):1489–94.

    Article  CAS  PubMed  Google Scholar 

  21. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11):784–94.

    Article  PubMed  Google Scholar 

  22. Bohm M, Borer J, Ford I, Gonzalez-Juanatey JR, Komajda M, Lopez-Sendon J, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol: Off J German Cardiac Soc. 2013;102(1):11–22.

    Article  Google Scholar 

  23. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England). 1999;353(9146):9–13.

  24. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002;106(17):2194–9.

    Article  PubMed  Google Scholar 

  25. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (London, England). 1999;353(9169):2001–7.

  26. Udelson JE. Ventricular remodeling in heart failure and the effect of beta-blockade. Am J Cardiol. 2004;93(9a):43b-8b.

    PubMed  Google Scholar 

  27. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–25.

    Article  CAS  PubMed  Google Scholar 

  28. Moran D, Buckley A, Daly K, Meaney B, Curtin R, O’Neill JO, et al. Heart rate awareness in patients with chronic stable heart failure. A multi-center observational study. Int J Cardiol. 2014;177(2):380–4. Study highlighting real world difficulties in achieving heart rate targets.

    Article  CAS  PubMed  Google Scholar 

  29. Bohm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet (London, England). 2010;376(9744):886–94.

    Article  Google Scholar 

  30. Ceconi C, Freedman SB, Tardif JC, Hildebrandt P, McDonagh T, Gueret P, et al. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011;146(3):408–14.

    Article  CAS  PubMed  Google Scholar 

  31. Akera T, Baskin SI, Tobin T, Brody TM. Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from, (Na + + K +)- activated ATPase. Naunyn Schmiedeberg’s Arch Pharmacol. 1973;277(2):151–62.

    Article  CAS  Google Scholar 

  32. Vitarelli A, Fedele F, Dagianti A, Penco M, Pastore LR, Dagianti A. A reexamination of the hemodynamic effects of digitalis relative to ventricular dysfunction. Cardiology. 1995;86(2):94–101.

    Article  CAS  PubMed  Google Scholar 

  33. Arnold SB, Byrd RC, Meister W, Melmon K, Cheitlin MD, Bristow JD, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med. 1980;303(25):1443–8.

    Article  CAS  PubMed  Google Scholar 

  34. Gheorghiade M, Hall V, Lakier JB, Goldstein S. Comparative hemodynamic and neurohormonal effects of intravenous captopril and digoxin and their combinations in patients with severe heart failure. J Am Coll Cardiol. 1989;13(1):134–42.

    Article  CAS  PubMed  Google Scholar 

  35. Covit AB, Schaer GL, Sealey JE, Laragh JH, Cody RJ. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure. Am J Med. 1983;75(3):445–7.

    Article  CAS  PubMed  Google Scholar 

  36. Newton GE, Tong JH, Schofield AM, Baines AD, Floras JS, Parker JD. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol. 1996;28(1):155–61.

    Article  CAS  PubMed  Google Scholar 

  37. The effect of digoxin on mortality and morbidity in patients with heart failure. The New England journal of medicine. 1997;336(8):525–33.

  38. Patel N, Ju C, Macon C, Thadani U, Schulte PJ, Hernandez AF, et al. Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. JACC Heart failure. 2016.

  39. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, et al. Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. J Am Coll Cardiol. 2014;64(7):660–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Castagno D, Petrie MC, Claggett B, McMurray J. Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J. 2012;33(9):1137–41.

    Article  CAS  PubMed  Google Scholar 

  41. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991;83(1):52–60.

    Article  CAS  PubMed  Google Scholar 

  42. Group TMDPTR. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988;319(7):385–92.

    Article  Google Scholar 

  43. Infarction TDSGoViM. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II). The American journal of cardiology. 1990;66(10):779–85.

  44. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.

    Article  PubMed  Google Scholar 

  45. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.

    Article  CAS  PubMed  Google Scholar 

  46. Torp-Pedersen C, Metra M, Spark P, Lukas MA, Moullet C, Scherhag A, et al. The safety of amiodarone in patients with heart failure. J Card Fail. 2007;13(5):340–5.

    Article  CAS  PubMed  Google Scholar 

  47. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–87.

    Article  PubMed  Google Scholar 

  48. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268–76.

    Article  CAS  PubMed  Google Scholar 

  49. Frankenstein L, Nelles M, Slavutsky M, Schellberg D, Doesch A, Katus H, et al. Beta-blockers influence the short-term and long-term prognostic information of natriuretic peptides and catecholamines in chronic heart failure independent from specific agents. J Heart Lung Trans: Off Publ Int Soc Heart Trans. 2007;26(10):1033–9.

    Article  Google Scholar 

  50. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, et al. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004;109(13):1674–9.

    Article  CAS  PubMed  Google Scholar 

  51. De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008;10(6):550–5.

    Article  PubMed  Google Scholar 

  52. Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, et al. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61(2):127–37.

    Article  CAS  PubMed  Google Scholar 

  53. Schuster A, Tang WH. Ivabradine in heart failure: to SHIFT or not to SHIFT. Current Heart Failure Rep. 2011;8(1):1–3.

    Article  Google Scholar 

  54. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–9.

    Article  PubMed  Google Scholar 

  55. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation. 2003;107(23):2920–5.

    Article  PubMed  Google Scholar 

  56. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100(19):1506–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Cubbon RM, Ruff N, Groves D, Eleuteri A, Denby C, Kearney L, et al. Ambulatory heart rate range predicts mode-specific mortality and hospitalisation in chronic heart failure. Heart. 2016;102(3):223–9.

    Article  CAS  PubMed  Google Scholar 

  58. Carson P, Wertheimer J, Miller A, O’Connor CM, Pina IL, Selzman C, et al. The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. JACC Heart Failure. 2013;1(5):400–8.

    Article  PubMed  Google Scholar 

  59. McCarthy JF, McCarthy PM, Starling RC, Smedira NG, Scalia GM, Wong J, et al. Partial left ventriculectomy and mitral valve repair for end-stage congestive heart failure. Eur J Cardio-thoracic Surg: Off J Eur Assoc Cardio-thoracic Surg. 1998;13(4):337–43.

    Article  CAS  Google Scholar 

  60. O’Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Connolly Hospital Blanchardstown, Blanchardstown, Dublin 15, Dublin, Ireland

    Mark Hensey & James O’Neill

Authors
  1. Mark Hensey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James O’Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James O’Neill.

Ethics declarations

Conflict of Interest

M. Hensey reports non-financial support from Bristol Myers Squibb, non-financial support from Daiichi Sankyo, non-financial support from Servier, and personal fees from Servier.

J. O’Neill declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hensey, M., O’Neill, J. Is Heart Rate a Norepiphenomenon in Heart Failure?. Curr Cardiol Rep 18, 91 (2016). https://doi.org/10.1007/s11886-016-0764-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-016-0764-3

Keywords

Search

Navigation